Perfusion Tech ApS: Financial statements 2022
CVR: 38238213
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -4,201,186 and a net result of DKK -6,556,178 compared with DKK -2,117,687 the year before. Equity in the 2022 report amounted to DKK 1,169,653. The solvency ratio was 23.9%. The company had 7 employees in the financial year.
- Gross Profit
- DKK -4,201,186
- Profit/Loss
- DKK -6,556,178
- Equity
- DKK 1,169,653
- Total Assets
- DKK 4,887,954
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -4.2 mio. | -6.6 mio. | 1.2 mio. | 7 |
| 2021 | - | -1.1 mio. | -2.1 mio. | -3.9 mio. | 4 |
| 2020 | - | -1.1 mio. | -1.5 mio. | -1.8 mio. | 3 |
| 2019 | - | -539 t. | -596 t. | -329 t. | 1 |
| 2018 | - | -262 t. | -238 t. | -453 t. | - |
Official annual report
Keep an eye on Perfusion Tech ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of October 24, 2022, Sten Scheibye has joined the board of directors of Perfusion Tech ApS.
As of October 24, 2022, Mads Aagaard Linde Madsen has left the board of directors of Perfusion Tech ApS.
As of October 1, 2022, Pernille Charlotte Singer is registered as director of Perfusion Tech ApS.
Perfusion Tech ApS has published its annual report for 2021. Gross profit came to DKK -1,066,804, and the net result was DKK -2,117,687.
As of March 21, 2022, Henrik Christensen has joined the board of directors of Perfusion Tech ApS.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The board consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. According to the 2025 annual report, the company had an average of 11 employees. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity in the 2025 report amounted to DKK -9,640,655.